Premium
Continuous intravenous infusion of TRH‐T: clinical, cardiovascular and endocrinological effects
Author(s) -
Formisano R.,
Ruggieri S.,
Cerbo R.,
Lucarelli F.,
Vuano G. De,
Parmegiani M.,
Agnoli A.,
Attanasio A.,
Capria A.,
Piccolo C. G. C.,
Fabrizi E.,
Cannata D.
Publication year - 1991
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1991.tb05005.x
Subject(s) - medicine , placebo , blood pressure , heart rate , anesthesia , ataxia , continuous infusion , cardiology , alternative medicine , pathology , psychiatry
Seven patients, six suffering from amyotrophic lateral sclerosis (ALS) and one from Friedreich ataxia, were treated with a placebo i.v. infusion during the first day and with TRH‐T i.v. infusion at a rate of 2 mg/h for 8 h daily (total daily dosage 16 mg) on the 2 consecutive days. Continuous blood pressure (BP) and EKG monitorings were performed during 3 days infusion. Blood samples were collected for endocrinological evaluations. The neurological evaluation after acute TRH‐T treatment showed an objective improvement in 3 of the 8. We found significantly higher values of systolic (max. difference of 10.1 mm Hg) and diastolic (max. difference of 8.8 mm Hg) BP than during placebo, beginning from the 5th h of the infusion (p < 0.05). A trend in progressive increase of the heart rate (HR) reached statistical significance (p < 0.01) at the 8th h of the second TRH‐T infusion. The cardiovascular changes during the i.v. continuous TRH‐T infusions were clinically irrelevant and never required the interruption of the treatment.